US IPO Market 2026: 123 Listings Raise $149B Despite Fewer Deals

Share

Renaissance Capital counts 123 US IPOs priced in 2026, with $149.0 billion raised on a perimeter limited to offerings of at least $50 million in market capitalization. The market is smaller in deal count but far larger in dollar terms. Several statistics, however, do not reconcile with one another, and the calendar lists two large offerings for November 2026.

๐Ÿ”‘ Key takeaways

  • 123 IPOs priced in 2026, down 35.9% according to the publication (39.1% on the raw totals of 123 versus 202).
  • $149.0 billion raised, with proceeds up 314.7%.
  • 217 filings, down 9.2% year on year.
  • Anthropic (ANT) and RegenLab USA (RGNA) appear on the calendar for the week of November 16, 2026, with no public listing date.

Fewer deals, far more capital

Renaissance Capital’s cumulative statistics describe a market moving at two speeds. The number of priced offerings is falling sharply, while capital raised is climbing fast. On the perimeter retained, the drop in deal count is more than offset by the jump in proceeds, which suggests that average deal sizes have risen considerably, although the source does not break down individual offerings.

The main indicators in the publication are the following:

  • Priced IPOs: 123, with a reported change of -35.9%.
  • Capital raised: $149.0 billion.
  • Change in proceeds: +314.7% year on year.
  • Filings: 217, a change of -9.2%.
  • Most represented sector: SPACs (special purpose acquisition companies), with 158 listings.

Monthly data adds context. June 2026 was the busiest month with 19 IPOs, and September the quietest with 7. In 2025, July led with 26 deals and December was lowest with 8.

Indicator20262025
Priced IPOs123202
Busiest monthJune (19)July (26)
Quietest monthSeptember (7)December (8)
Filings217Not reported

Figures that do not yet add up

The first inconsistency concerns the change in deal count. On the raw totals, 123 IPOs in 2026 against 202 in 2025 is a decline of 39.1%, not the 35.9% shown in the publication. This 3.2-point gap cannot be explained from the material provided.

The source does not say whether the 35.9% figure compares the 2026 year-to-date count with the equivalent 2025 period rather than with the full 2025 year. It also does not confirm whether both monthly totals are limited to the $50 million threshold. As a purely arithmetic check, a 35.9% decline from 123 deals would imply a base of about 192 deals (123 / 0.641), a figure that appears nowhere in the data.

The second issue concerns SPACs, which account for 158 listings, the highest count in any sector. That figure cannot be reconciled with the other data: it is above the 123 priced IPOs but below the 217 filings. Renaissance Capital does not specify whether it counts priced offerings, regulatory filings or a different perimeter.

The 158 SPACs therefore cannot be presented as a subset of the 123 priced IPOs. Any sector analysis built on that number should be treated as provisional.

ETF claims and the Morningstar verdict

Renaissance Capital promotes its IPO ETF with the messages “almost no overlap with the S&P 500” and “contains only new issues”. According to the promotional block, the fund’s holdings average 1.3 years of age, versus 43 years for the S&P 500, with overlap of 0.1% by weight as of January 1, 2026.

The promotional block does not specify whether these characteristics refer to the US IPO ETF or to the international version, although the page links to both. They cannot be attributed to the international fund IPOS without further evidence.

The only fund explicitly analysed in the sources is the Renaissance International IPO ETF (ticker IPOS), assessed by Morningstar through three pillars: Process, which asks whether the objective and investment process are reasonable, clearly defined and repeatable; People, which measures the experience and capabilities of the management team; and Parent, which evaluates the priorities of the parent organisation and their alignment with investors. The central question is whether IPOS will outperform in the future.

“Renaissance International IPO ETF has a negative, quantitatively derived Morningstar Medalist Rating. This rating indicates that the model sees limited potential for the strategy to outperform its peers on a risk-adjusted basis over a full market cycle.”

Morningstar Automated Analysis, analyst summary

The rating was assessed as of September 30, 2026, and the analysis was published on October 27, 2026. It concerns the risk-adjusted outlook of one fund strategy, not the US IPO market as a whole.

Calendar: Anthropic and RegenLab USA ahead

The calendar consulted, dated the week of November 16, 2026, lists two offerings. Anthropic (ticker ANT) is offering 825.0 million shares in a range of $70 to $78 per share, with a displayed deal size of 61,050 million dollars, or $61.05 billion. That size implies an average price of about $74 per share, consistent with the range. RegenLab USA (ticker RGNA) is offering 2.5 million shares between $6 and $8, for $18 million, implying a price of about $7.20.

IssuerTickerDisplayed sizePrice rangeLead underwriter
AnthropicANT$61.05 billion$70 to $78Goldman, Morgan Stanley
RegenLab USARGNA$18 million$6 to $8StoneX

Both offerings are listed on Nasdaq, and no NYSE offering appears in the period reviewed. Listing dates are hidden behind the paid IPO Pro access. Neither offering is part of the 123 priced IPOs counted in the statistics.

The sources contain no first-day trading data, no post-listing performance and no information on the S&P 500. No broader market reaction to the change in IPO volume is documented.


Conclusion: a selective market, data still to be consolidated

The 2026 US IPO market combines fewer deals with sharply higher proceeds. That pattern is consistent with capital concentrating in larger offerings, but the published figures do not yet quantify it reliably. The reported decline, the SPAC count and the exact scope of the statistics all need clarification before any firm conclusion can be drawn.

Three scenarios merit monitoring. In the first, the announced offerings price within their ranges, confirming the rise in proceeds. In the second, a methodological adjustment by Renaissance Capital revises the published figures, including the 35.9% decline. In the third, the drop in filings (217, down 9.2%) translates into a lasting slowdown in the calendar. The available sources do not allow any of these scenarios to be ruled in or out.

Sources

Cet article est publiรฉ ร  titre informatif et รฉducatif. Il ne constitue en aucun cas un conseil en investissement. Faites vos propres recherches (DYOR) avant toute dรฉcision.

Disclaimer: this content is for information purposes only and is not financial advice. Cryptocurrencies are highly volatile: you may lose all of your capital. Always do your own research. Legal notice
Telemac
Telemachttp://cryptoinfo.ch
Passionnรฉ de nouvelles technologies, jโ€™explore lโ€™univers de la blockchain et des cryptomonnaies pour partager lโ€™actualitรฉ et les innovations du secteur.

Read More

Items